Assessing the association between homologous recombination deficiency scores and treatment response in localized and metastatic prostate cancer.

J Pathol Clin Res · 2026 · PMC12802083 · PMID 41532774

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

showed a trendp = 0.130not close (p > 0.1)

In the mHSPC cohort, patients with HRD scores ≥21 showed a trend toward worse PSA response rates (23/29 versus 30/32, p = 0.130; Figure 2D ), PSA‐PFS (median: 31.6 months versus not reached, p = 0.160; Figure 2E ), and rPFS (median: 45.5 months versus not reached, p = 0.550; Figure 2F ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.